Aug 11, 2023 / 12:15PM GMT
Sachin Jain - BofA Securities, Research Division - MD & Research Analyst
Okay. Everyone, should we get kicked off. Thank you very much. So thanks very much everyone. It's Sachin Jain here from the European Pharma team at BofA. Thank you very much to everyone for coming. It's a real pleasure to be hosting Novo post their results. And obviously, we have a fuller room than anticipated, obviously, Tuesday was a very good day and so demand build. So apologies were tightened here. We have an hour and 15, we have the entire C-suite. I think we have half an hour of presentation and for questions.
So Lars, with that further over to you. Thanks very much.
Lars Fruergaard Jorgensen - Novo Nordisk A/S-President - CEO & Member of Management Board
Thank you, Sachin. And thank you, Bank of America for hosting us. Indeed, it is a great week for us. We're very excited. It's great to be on the road and talk about where the company is. We will go through the slides relatively quickly, so we can get into the Q&A. I
Q2 2023 Novo Nordisk A/S Earnings Call (London-Based Investors) Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot